Skip to Content

Chlorothiazide Sodium Injection

Last Updated: January 16, 2018
Status: Current

Chlorothiazide Sodium Injection

Products Affected - Description
  • Sodium Diuril injection, Akorn
    500 mg, vial, 1 count (NDC 76478-0711-40)

    Chlorothiazide injection, Akorn
    500 mg, vial, 1 count (NDC 17478-0419-40)

 
Chlorothiazide injection, American Regent
500 mg, vial, 1 count (NDC 00517-1820-01)
 
Chlorothiazide injection, Fresenius Kabi
500 mg, vial, 1 count (NDC 63323-0658-20)
 
Chlorothiazide injection, Mylan Institutional
500 mg, vial, 1 count (NDC 67457-0263-30)
 
Chlorothiazide injection, Sagent
500 mg, vial, 1 count (NDC 25021-0305-20)
Reason for the Shortage
    • Akorn has chlorothiazide injection on shortage due to manufacturing delays.
    • Sagent has chlorothiazide injection on shortage due to increased demand.
    • Sun Pharma refuses to provide availability information on any of their products.
Available Products
  • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Akorn has chlorothiazide 500 mg vials on back order and the company estimates a release date of mid-February 2018. Akorn has Sodium Diuril injection on back order and the company cannot estimate a release date.
    • American Regent has chlorothiazide 500 mg vials available in limited supply.
    • Fresenius Kabi has chlorothiazide 500 mg vials on back order and the company estimates a release date of late-February to early-March 2018.
    • Mylan Institutional has chlorothiazide 500 mg vials on back order and the company estimates a release date of mid-January 2018.
    • Sagent has chlorothiazide 500 mg vials on back order and the company estimates a release date of December 2017.

Updated

January 16, 11 and 10, 2018; December 11, 2017, University of Utah, Drug Information Service. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide